HomeMarketsEarningsAmgen (AMGN) Sales Higher After Obesity Drug Results

Amgen (AMGN) Sales Higher After Obesity Drug Results

Amgen (AMGN) sales are higher after early results from a study of an obesity drug. Renita Young discusses this as the Amgen CEO is “very encouraged” by the results of the obesity drug study. Tune in to find out more about the stock market today.

Morning Trade Live

03 May 2024

SHARE

ON AIR
education
6:00 am
Schwab 2026 Outlook
replay
education
12:00 am
Schwab 2026 Outlook
REPLAY
1:00 am
Market Overtime
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Market Overtime
REPLAY
4:30 am
Market Overtime
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
Market Overtime
REPLAY
ON AIR
education
6:00 am
Schwab 2026 Outlook
REPLAY
7:00 am
Market Overtime
REPLAY
education
8:00 am
Your First Trade
REPLAY
education
8:30 am
Your First Trade
REPLAY
9:00 am
Fast Market
REPLAY
10:00 am
Market Overtime
REPLAY
10:30 am
Market Overtime
REPLAY
11:00 am
Market Overtime
REPLAY
11:30 am
Market Overtime
REPLAY
education
12:00 pm
Schwab 2026 Outlook
REPLAY
1:00 pm
Market Overtime
REPLAY
education
2:00 pm
Your First Trade
REPLAY
education
2:30 pm
Your First Trade
REPLAY
3:00 pm
Fast Market
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market Overtime
REPLAY
5:00 pm
Market Overtime
REPLAY
5:30 pm
Market Overtime
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Market Overtime
REPLAY
education
8:00 pm
Your First Trade
REPLAY
education
8:30 pm
Your First Trade
REPLAY
9:00 pm
Fast Market
REPLAY
10:00 pm
Market Overtime
REPLAY
10:30 pm
Market Overtime
REPLAY
11:00 pm
Market Overtime
REPLAY
11:30 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor